CORDIS · 115337 · FP7
PREDICT-TB Model-based preclinical development of anti-tuberculosis drug combinations
Coordinator: GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL (ES)
Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical systems which do not capture in vivo pharmacodynamics of heterogeneous states of M.tuberculosis.These systems are diverse and their predictive power for clinical trial outcomes is uncertain, escalating…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €14.8M toward a total project budget of €28.6M — a funding rate of 52%, with the remainder covered by the consortium partners. The project runs over approximately 5.5 years from 2012-05-01 to 2017-10-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from ES
see all →- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · HORIZON · €206.9M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · H2020 · €89.8M
- DRIVER+ — DRiving InnoVation in crisis management for European Resilience607798 · FP7 · €33.5M
- READI — Research in Europe and Diversity Inclusion101166227 · HORIZON · €31.5M
- GREENH2ATLANTIC — A 100 MW FLEXIBLE GREEN HYDROGEN PRODUCTION PROCESS SOURCING HYBRID RENEWABLE ENERGY AND SUPPLYING GREEN HYDROGEN TO MULTIPLE END-USES101036908 · H2020 · €30.0M
- PERSEUS — Protection of European seas and borders through the intelligent use of surveillance261748 · FP7 · €27.8M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €14.8M toward a total project budget of €28.6M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL (ES).
- What is the project timeline?
- The project runs from 2012-05-01 to 2017-10-31 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115337.